Research & Education

Proton Beam Therapy for Lung Cancer

Friday, February 12, 2016 - 6 p.m. CET - Recording Available

The IASLC Education Committee is pleased to announce the first program in the 2016 series of Live Webinars presented by the Advanced Radiation Therapy (ART) Committee.  This subcommittee is focused on the development and execution of educational and informational programs addressing state of the art radiation therapy for lung cancer. This live program will be moderated by Francoise Mornex, MD, PhD and feature presentations by Ramesh Rengan, MD, PhD and Tony Wong, PhD, DABR.

Françoise MORNEX Ramesh Rengan Tony Wong 

Program Chair
PR Françoise Mornex , MD, PhD

Département de Radiothérapie
Centre Hospitalier Lyon Sud
LYON, France

Ramesh Rengan MD, PhD

Associate Professor,
Department of
Radiation Oncology,
University of Washington
Associate Member,
Fred Hutchinson Cancer Research Center
Medical Director,
SCCA Proton Therapy Center
Seattle, Washington

Tony Wong, PhD, DABR

Director of Medical
Physics & Dosimetry
Seattle Cancer Care
Alliance Proton Therapy Center
Seattle, Washington

Name of Reviewer(s): 

              

Fred Hirsch, MD, PhD –Speakers Bureau/Advisory Board: Astrazeneca, Genentech, BMS, Lilly and Abbvie.

Name of Planner(s): 

 

     Deb Whippen-Nothing to Disclose

Name of Activity: 

 

Proton Beam Therapy for Lung Cancer

Date of Activity:

 

February 12, 2016

Faculty/Speaker(s):

Financial DISCLOSURES

COI Resolution: Ensure the activity includes a balanced discussion of alternative therapies.

 

 

PR Françoise Mornex , MD, PhD-Moderator- Consulting for: Lilly, Roche and Boehringrt-Ingelheim

Ramesh Rengan MD, PhD- Advisory Board and Member: Apollo Oncology Indi

 

Tony Wong, PhD, DABR- Nothing to Disclose

Type of Activity: 

 Live Course

  Internet Live Course (Webinar)

 Internet Enduring Material

Are there Commercial Supporters for this activity?

    Yes    

If yes, please list: This series is partially supported by an unrestricted grant from Elekta

 

This program will review the current strengths and limitations of the current standard of care in the radiotherapeutic management of non-small cell lung cancer (NSCLC). We will discuss the potential rationale for proton beam radiotherapy in the management of NSCLC and the clinical data that are available.

The Role of Proton Beam Radiotherapy in the Management of Non-Small Cell Lung Cancer - Ramesh Rengan, MD, PhD

This presentation will examine proton therapy as a new tool for treating lung cancer with fewer toxicities such as pneumonitis and esophagitis, in particular for stage III NSCLC patients. Its superior dose distribution as compared to conventional photon therapy offers further advantages for re-irradiation when tumors arise in or near previously radiated tissues. In addition, proton therapy is also beneficial to some unfavorable patients with early stage NSCLC. We will identify ongoing clinical trials and current areas of active research investigation in the efficacy of proton beam radiotherapy for NSCLC.

Proton Therapy for Lung Cancer: A Physicist's Perspective - Tony Wong, PhD

This presentation will discuss the benefits of proton therapy using uniform scanning and pencil beam scanning techniques in treating lung cancer. We will describe common mitigation strategies to minimize the interplay effect between tumor motion and proton beam delivery with pencil beam scanning technique.

At the end of this activity learners will be able to:

  • Examine proton therapy as a new tool for treating lung cancer with fewer toxicities such as pneumonitis and esophagitis
  • Compared to conventional photon therapy offers further advantages for re-irradiation when tumors arise in or near previously radiated tissues
  • Discuss the benefits of proton therapy using uniform scanning and pencil beam scanning techniques in treating lung cancer.
  • Describe common mitigation strategies to minimize the interplay effect between tumor motion and proton beam delivery with pencil beam scanning technique.

 

DOWNLOAD RECORDING

CME Information:

Financial/Commercial Relationships DISCLOSURES

A Conflict of Interest (COI) is created and exists when individuals in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used, on patients that benefits the individual in any financial amount and therefore, may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected. 

 This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/moderators/peer reviewers et. al. conflicts of interest  were identified, reviewed and resolved from all individuals involved in the development  or able to influence and control the content of this CME activity; IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.  Any individual who failed or refused to disclose relevant financial relationships was disqualified from this CME activity and removed from any of IASLC CME activity presentation.

All commercial relationships and conflicts of interest that are identified are thoroughly vetted by IASLC Ethics Committee, CME Subcommittee, and Independent reviewer. COI will be evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

CREDIT STATEMENT

IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC CME designates this Internet Live Course activity for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

GOAL & PURPOSE

This program will review the current strengths and limitations of the current standard of care in the radiotherapeutic management of non-small cell lung cancer (NSCLC). We will discuss the potential rationale for proton beam radiotherapy in the management of NSCLC and the clinical data that are available.

TARGET AUDIENCE

This CME live webinar series is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists and advanced practice nurses and physicians' assistants.

DISCLAMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Thank you for your participation.

IASLC Financial/Commercial Relationships and Conflicts of Interest Policy

IASLC Honoraria Policy

IASLC Commercial Support Agreement (LOA)

If you are interested in obtaining the CME Credits for these sessions you must indicate this when you register for the program. CME Credit is only available for those that participate in the Live Session.

Location Local time Time zone UTC offset
New York (U.S.A. - New York) Friday, February 12, 2016 at 12:00:00 Noon EST UTC-5 hours
Paris (France) Friday, February 12, 2016 at 6:00:00 PM CET UTC+1 hour
Seattle (U.S.A.) Friday, February 12, 2016 at 9:00:00 AM PST UTC-8 hours 
London (United Kingdom - England) Friday, February 12, 2016 at 5:00:00 PM GMT UTC
Barcelona (Spain) Friday, February 12, 2016 at 6:00:00 PM CET UTC+1 hour
Amsterdam (Netherlands) Friday, February 12, 2016 at 6:00:00 PM CET UTC+1 hour
Dublin (Ireland) Friday, February 12, 2016 at 5:00:00 PM GMT UTC
Geneva (Switzerland) Friday, February 12, 2016 at 6:00:00 PM CET UTC+1 hour
Berlin (Germany) Friday, February 12, 2016 at 6:00:00 PM CET UTC+1 hour
Vienna (Austria) Friday, February 12, 2016 at 6:00:00 PM CET UTC+1 hour
Corresponding UTC (GMT) Friday, February 12, 2016 at 05:00:00 PM    

How to use the Time Zone Converter